Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lucid DiagnosticsLUCD -11.74%20 EV-to-OCF is -4.39 as of Jul. 16, 2026. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Lucid Diagnostics ranks better than 73.22% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Lucid Diagnostics's Enterprise Value is $202.70 Mil.
Lucid Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-46.12 Mil. Therefore, Lucid Diagnostics's EV-to-OCF for today is -4.39.
The historical rank and industry rank for Lucid Diagnostics's EV-to-OCF or its related term are showing as below:
LUCD'
s EV-to-OCF Range Over the Past 10 Years
Min: -42.55 Med: -2.3 Max: -0.7
Current: -4.39
During the past 7 years, the highest EV-to-OCF of Lucid Diagnostics was -0.70. The lowest was -42.55. And the median was -2.30.
LUCD's EV-to-OCF is ranked better than 73.22% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 8.05
vs LUCD: -4.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lucid Diagnostics's PE Ratio (TTM) for today is calculated as:
Lucid Diagnostics's share price for today is $1.02.
Lucid Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lucid Diagnostics EV-to-OCF Related Terms
Lucid Diagnostics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lucid Diagnostics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's EV-to-OCF falls into.
Lucid Diagnostics's current Enterprise Value is $202.70 Mil.
Lucid Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a EV-to-OCF of -4.39 as of Jul. 16, 2026. According to the industry distribution chart, Lucid Diagnostics ranks #229 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Lucid Diagnostics' EV-to-OCF too high?
Lucid Diagnostics' current EV-to-OCF is -4.39. Based on the distribution chart, Lucid Diagnostics ranks #229 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' EV-to-OCF compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #229 out of 855 companies for EV-to-OCF. This puts Lucid Diagnostics in the upper half of its industry. The industry median EV-to-OCF is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 8.05, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current EV-to-OCF is -4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $1.02 — trading 24.4% above its estimated fair value. The current EV-to-OCF is -4.39. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current EV-to-OCF is -4.39 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.02 is trading 24.4% above its estimated GF Value™ of $0.82.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
EV-to-OCF: -4.39
GF Value™: $0.82 vs. price of $1.02 (24.4% above fair value)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score
Get the complete analysis for LUCD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
